Autoantibody and metalloproteinase activity in early arthritis

Abstract

Objectives The aim of the study was to evaluate the frequency of anti-mutated citrullinated vimentin antibodies (a-Sa), anticitrullinated α-enolase peptide 1 antibodies (a-CEP-1), anti-filaggrin antibodies (AFAs), heterogeneous nuclear ribonucleoprotein compies/anti-RA33-antibodies (a-hnRNP/RA33), anti-carbamylated protein antibodies (a-CarP), and metalloproteinase (MMPs) activity in patients with early inflammatory arthritis (EIA). Methods Seventy-four patients with EIA: 51 diagnosed with RA (rheumatoid arthritis) and 23 with UA (undifferentiated arthritis), and 20 healthy volunteers were enrolled to the study. Inflammatory markers, rheumatoid factor (RF), and antibodies mentioned above were assessed in all patients. Results In the EIA group, we observed significantly higher concentration of a-CEP-1 (65.8 ± 111.6 RU/mL) than in controls (2.0 ± 0.0 RU/mL). In RF(+) RA patients, we observed higher concentration of a-Sa and a-CEP-1 than in other groups. A-Sa were positive in 69% of RF(+) RA, 37% of RF(−) RA, 26% of UA patients and in 10% of controls. A-CEP-1 were positive in 77% of RF(+) RA patients, in 56% of RF(−) RA patients, in 8.7% of UA patients, but they were negative in controls. In patients with RF(+) RA, positive a-CarP were present statistically significantly more often than in RF (−) RA patients. No statistically significant difference in frequency of a-hnRNP/RA33 and AFA between RF(+) RA, RF(−) RA, and UA was observed. Conclusions Our results suggest that a-CEP-1 may help in differentiation between RF(−) RA and UA. a-CEP-1 and a-Sa may be useful while diagnosing EIA. a-CarP may be used in differentiation of RA RF(−) and UA. However, a follow-up study is needed to evaluate the prognostic value of analyzed antibodies. Keywords Anti-carbamylated protein antibodies (a-CarP). Anti-citrullinated α-enolase peptide 1 antibodies (a-CEP-1). Anti-filaggrin antibodies (AFA). Anti-mutated citrullinated vimentin antibodies (a-Sa). Early inflammatory arthritis. Heterogeneous nuclear ribonucleoprotein compies/anti-RA33-antibodies (a-hnRNP/RA33). Metalloproteinases (MMP). Rheumatoid arthritis

Diagnostic value of anti‐citrullinated α‐enolase peptide 1 antibody in patients with rheumatoid arthritis: A systematic review and meta‐analysis

“…Therefore, an inconsistent antigen source may adversely affect the capability for detection of the anti-CEP 1 antibody and the diagnostic performance of home-made ELISA kits. Of note, although the meta-regression showed that 3 factors may contribute to the heterogeneity, the subgroup analysis did not explore the no- [15][16][17][20][21][22]31,34,35,37,38 The results were significantly different due to variations in sample size, study design or patient ethnicity, so further study is needed to investigate the reasons for these variations. Additionally, the first presentation of the anti-CEP antibody can be earlier than the increase in the anti-CCP antibody.…”

“…[15][16][17][18][19][20][21][22][23][24][25][27][28][29][30][31][32][33][34][35]37,38 Most of the studies used ELISAs to detect the anti-CEP 1 antibody by commercial ELISA kits or a self-established ELISA method. [15][16][17]19,22,24,25,28,29,[31][32][33][35][36][37][38] Two types of CEP-1 peptide sequences were used as coating antigens in the self-established ELISA methods: one was a CKIHA(cit)EIFDS(cit)GNPTVEC (cyclic) with C-terminal and N-terminal cysteines to facilitate cyclization in 6 included studies, 25,31,33,35,37,38 and another was a KIHA(cit)EIFDS(cit) GNPTVE without cysteine in 4 of the studies. 24,28,29,32 Detailed...…”

“…Among the 24 studies included in the meta-analysis, the sensitivity of the anti-CEP 1 antibody to RA ranged 17.4%-72.0%, and the specificity of the anti-CEP 1 antibody to RA ranged 76%-100%. Eleven studies out of 24 included studies showed the prevalence of the anti-CEP 1 antibody in the anti-CCP antibody negative RA patients or anti-CCP antibody-positive RA patients, [15][16][17][20][21][22]31,34,35,37,38 and the prevalences of the anti-CEP 1 antibody in the 2 groups of RA patients were 0%-41.2% and 32.6%-91.0%, respectively. The pooled sensitivity and specificity were 44% (95% CI: 38%-51%, P < .0001, I 2 = 97.02%) and 97% (95% CI: 96%-98%, P < .0001, I 2 = 92.77%), respectively (Figure 3A,B).…”

ACCP-negative rheumatoid arthritis – clinical and immunological features

“…Известно, что ММП-3 отражает активность РА и позволяет прогнозировать развитие эрозий [54,55]. Высокий уровень ММП-3 у АЦЦП-негативных пациентов с недифференцированным артритом может быть преди ктором развития РА (ДЧ=63,6%; ДС=81,5%) [56,57].…”